Hemogenyx Pharmaceuticals’ expands CBR platform to treat cancer
( ) , a biopharma company developing therapies and treatments for blood diseases, announces the potential expansion of its Chimeric Bait Receptor platform to treat cancers alongside viral diseases. Human macrophages, equipped with a tailored CBR, effectively eliminated Non-Hodgkin Lymphoma (NHL) cells in vitro, hinting at a promising treatment for stage III/IV NHL. The adaptable CBR design also shows promise against solid tumors like ovarian cancer and certain carcinomas.
Utilising AI-based protein simulations and in-house mRNA synthesis, the company accelerated R&D. AI tools swiftly assess CBR variants, while mRNA synthesis enables rapid construct development within days.
Preliminary tests against live SARS-CoV-2, the COVID-19 virus, revealed the effectiveness of CBR-equipped macrophages in vitro. Further optimisation and in vivo testing are underway in a BSL-3 facility by an external scientific team.
View from Vox
Hemogenyx Pharmaceuticals started its Chimeric Bait Receptor platform project prior to the COVID-19 pandemic as a new approach to combat emerging or not yet known viral infections. Data obtained during the initial period of development of the platform allowed the Company’s scientists to expand the potential use of CBR into the area of cancer treatment.
This year, it was announced that Hemogenyx pinpointed a key protein for a versatile CBR-based therapy that can combat various deadly viruses—Dengue, Ebola, Marburg, Zika, and Chikungunya. This innovation streamlines treatment, potentially addressing severe and often fatal diseases with limited existing remedies, eliminating the need for separate CBR constructs for each virus.
Today’s announcement is significant, given that NHL ranks as the 11th most common cancer, with around 540,000 new cases annually and roughly 260,000 deaths. In the US, it's estimated to affect 80,550 people, causing 20,180 deaths in 2023. A breakthrough therapy for NHL could significantly enhance treatment and survival rates.
Follow Hemogenyx Pharmaceuticals for more News and Updates:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.